Stock News•1 months ago
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
Amneal's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
MarketLens
Is Zai Lab's "Dual-Engine Strategy" Driving Global Growth
5 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•2 months ago
Zai Lab Q2 Earnings Call Highlights
Zai Lab's Q2 net product revenue rose 11% sequentially to $105.8 million, as the company continues investing in a pipeline aimed at transitioning into a global biopharmaceutical business.
Stock News•2 months ago
Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts
Hutchmed's oncology franchise growth, Fruzaqla international rollout, and improving China execution could boost recurring revenues. Late-stage immunology assets and pipeline options like Sovleplenib a...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
Apple (AAPL) Advances While Market Declines: Some Information for Investors
Stock News•1 hour ago
Nvidia-Backed Firmus Scraps Australian IPO, Citing Market Conditions
Stock News•1 hour ago
History Says Every S&P 500 Bull Market That Reached Its 4th Birthday Kept Going
Stock News•2 hours ago
Pilot and Tesla Open First Megacharger Site, Announce Three Additional Locations Opening Soon
Stock News•2 hours ago